Minimal clinically important differences for measures of treatment efficacy in Stevens-Johnson syndrome and toxic epidermal necrolysis

J Am Acad Dermatol. 2018 Dec;79(6):1150-1152. doi: 10.1016/j.jaad.2018.06.002. Epub 2018 Jun 8.

Authors

Whan B Kim¹, Brandon Worley¹, James Holmes², Elizabeth J Phillips³, Jennifer Beecker⁴

Affiliations

¹ Division of Dermatology, Department of Medicine, University of Ottawa, Ottawa, Canada.
² Wake Forest University School of Medicine, Ottawa, Canada.
³ Department of Medicine, Vanderbilt University Medical Center, Ottawa, Canada; Institute for Immunology & Infectious Diseases, Murdoch University, Ottawa, Canada.
⁴ Division of Dermatology, Department of Medicine, University of Ottawa, Ottawa, Canada. Electronic address: jbeecker@toh.ca.

No abstract available

MeSH terms

Clinical Trials as Topic
Dermatologists
Disease Progression
Humans
Length of Stay / statistics & numerical data
Minimal Clinically Important Difference
Professional Practice
Re-Epithelialization
Research Design
Stevens-Johnson Syndrome / drug therapy*
Stevens-Johnson Syndrome / pathology
Surgeons
Surveys and Questionnaires
Survival Rate
Treatment Outcome

Grants and funding